Pfizer ups guidance as it prepares to sell off generics divisionPfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared Share XPfizer ups guidance as it prepares to sell off generics divisionhttps://pharmaphorum.com/news/pfizer-ups-guidance-as-it-prepares-to-sell-off-generics-division/
Gilead eyes takeover of cancer biotech Tizona, despite its ties to AbbVieGilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – Share XGilead eyes takeover of cancer biotech Tizona, despite its ties to AbbViehttps://pharmaphorum.com/news/gilead-eyes-takeover-of-cancer-biotech-tizona-despite-its-ties-to-abbvie/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Novo Nordisk diversifies with $2.1bn deal to buy CorvidiaNovo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal Share XNovo Nordisk diversifies with $2.1bn deal to buy Corvidiahttps://pharmaphorum.com/news/novo-nordisk-diversifies-with-2-1bn-deal-to-buy-corvidia/
Celltrion buys drug portfolio from Takeda, ventures into chronic diseasesSouth Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Share XCelltrion buys drug portfolio from Takeda, ventures into chronic diseaseshttps://pharmaphorum.com/news/celltrion-ventures-into-chronic-diseases-with-takeda-portfolio-buy/
AstraZeneca ‘probably couldn’t run Gilead any better:’ analystAstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to Share XAstraZeneca ‘probably couldn’t run Gilead any better:’ analysthttps://pharmaphorum.com/news/astrazeneca-probably-couldnt-run-gilead-any-better-analyst/
AZ reportedly mulls biggest-ever pharma merger with GileadAlmost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – Share XAZ reportedly mulls biggest-ever pharma merger with Gileadhttps://pharmaphorum.com/news/az-reportedly-mulls-biggest-ever-pharma-merger-with-gilead/
Takeda posts surprise profit a year after Shire mega-mergerJapan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year Share XTakeda posts surprise profit a year after Shire mega-mergerhttps://pharmaphorum.com/news/takeda-posts-surprise-profit-a-year-after-shire-mega-merger/
No takeover approach, says COVID-19 vaccine developer BioNTechGermany’s BioNTech has said it has not received any takeover approaches after it began a high-profile coronavirus vaccine Share XNo takeover approach, says COVID-19 vaccine developer BioNTechhttps://pharmaphorum.com/news/biontech-plays-down-takeover-talk-ahead-of-covid-19-vaccine-trial/
